Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

OSAKA, Japan & CAMBRIDGE, Mass., November 08, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is the first and only selective

Related Keywords

China ,United States ,Cairo ,Al Qahirah ,Egypt ,Macau ,Cancer Institute ,Belgium ,Osaka ,Japan ,Hong Kong ,Australia ,Japanese ,Belgian ,Ahcene Djaballah ,Gastroenterol Hepatol ,Cathy Eng ,Jun Saito ,Teresa Bitetti ,Michael Sapienza ,Colorectal Cancer Alliance ,Takeda Pharmaceutical Company Limited ,National Cancer Institute ,International Agency For Research On Cancer ,International Normalized Ratio ,China National Medical Products Administration ,European Medicines Agency ,Exchange Commission ,Devices Agency ,Takeda Pharmaceuticals ,Vanderbilt University Medical Center ,Japan Pharmaceuticals ,Drug Administration ,First Targeted Therapy Approved ,Metastatic Colorectal Cancer ,Biomarker Status ,Prior Types ,More Than ,Overall Survival ,Corresponding Improvements ,Progression Free Survival ,Versus Placebo Plus Best Supportive Care ,Two Phase ,Manageable Safety Profile ,Previously Treated Patients ,Priority Review ,Global Oncology Business Unit ,Vanderbilt University Medical ,Chief Executive Officer ,Colorectal Cancer ,Medical Devices Agency ,Plantar Erythrodysesthesia ,Reversible Encephalopathy Syndrome ,Sunset Yellow ,Prescribing Information ,International Agency ,Annual Report ,Cancer Res ,Cancer Biol ,Soc Clin Oncol Educ ,Cancer Statistics ,Mortality Worldwide ,Rev Gastroenterol Hepatol ,Clinical Cancer Res ,Winding Road From Negative Predictive Factor ,Makeda ,Fruzaqla ,Targeted Therapy ,